This is a pretty simplistic view, the article talks about a different Surgisphere study where the conclusion is that a cheap and widely available drug is effective against covid-19 (the study also has its problems though):

"A third COVID-19 study using Surgisphere data has also drawn fire. In a preprint first posted in early April, Surgisphere founder and CEO Sapan Desai and co-authors conclude that ivermectin, an antiparasitic drug, dramatically reduced mortality in COVID-19 patients. In Latin America, where ivermectin is widely available, that study has led government officials to authorize the drug—although with precautions—creating a surge in demand in several countries."